660416-36-4 Usage
Description
3-Fluoro-5-(methoxycarbonyl)benzoic acid is a benzoic acid derivative featuring a fluorine atom at the 3-position and a methoxycarbonyl group at the 5-position. This chemical compound is widely utilized in organic synthesis and pharmaceutical research, known for its enzyme-inhibiting properties and potential therapeutic applications in treating various diseases. It also serves as a fundamental building block in the creation of more complex organic compounds, making it an indispensable asset in medicinal chemistry and drug discovery.
Uses
Used in Pharmaceutical Research:
3-Fluoro-5-(methoxycarbonyl)benzoic acid is used as a key intermediate in the development of pharmaceuticals for its ability to inhibit specific enzymes. This property makes it a promising candidate for the treatment of a range of diseases by modulating enzyme activity, which can have therapeutic benefits.
Used in Organic Synthesis:
In the field of organic synthesis, 3-fluoro-5-(methoxycarbonyl)benzoic acid is employed as a versatile building block. Its unique structure allows for the creation of more complex organic compounds, facilitating the advancement of chemical research and the development of novel materials and substances.
Used in Medicinal Chemistry:
3-Fluoro-5-(methoxycarbonyl)benzoic acid plays a significant role in medicinal chemistry, where it is used to explore and understand the structure-activity relationships of potential drug candidates. Its presence in compounds can influence their pharmacological properties, making it a valuable tool in the design and optimization of new therapeutic agents.
Used in Drug Discovery:
As a component in drug discovery processes, 3-fluoro-5-(methoxycarbonyl)benzoic acid aids researchers in identifying and optimizing lead compounds with desired biological activities. Its incorporation into various chemical structures can lead to the discovery of new drugs with improved efficacy and safety profiles.
Check Digit Verification of cas no
The CAS Registry Mumber 660416-36-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,6,0,4,1 and 6 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 660416-36:
(8*6)+(7*6)+(6*0)+(5*4)+(4*1)+(3*6)+(2*3)+(1*6)=144
144 % 10 = 4
So 660416-36-4 is a valid CAS Registry Number.
660416-36-4Relevant articles and documents
Peptidomimetic plasmepsin inhibitors with potent anti-malarial activity and selectivity against cathepsin D
Zogota, Rimants,Kinena, Linda,Withers-Martinez, Chrislaine,Blackman, Michael J.,Bobrovs, Raitis,Pantelejevs, Teodors,Kanepe-Lapsa, Iveta,Ozola, Vita,Jaudzems, Kristaps,Suna, Edgars,Jirgensons, Aigars
supporting information, p. 344 - 352 (2018/12/11)
Following up the open initiative of anti-malarial drug discovery, a GlaxoSmithKline (GSK) phenotypic screening hit was developed to generate hydroxyethylamine based plasmepsin (Plm) inhibitors exhibiting growth inhibition of the malaria parasite Plasmodium falciparum at nanomolar concentrations. Lead optimization studies were performed with the aim of improving Plm inhibition selectivity versus the related human aspartic protease cathepsin D (Cat D). Optimization studies were performed using Plm IV as a readily accessible model protein, the inhibition of which correlates with anti-malarial activity. Guided by sequence alignment of Plms and Cat D, selectivity-inducing structural motifs were modified in the S3 and S4 sub-pocket occupying substituents of the hydroxyethylamine inhibitors. This resulted in potent anti-malarials with an up to 50-fold Plm IV/Cat D selectivity factor. More detailed investigation of the mechanism of action of the selected compounds revealed that they inhibit maturation of the P. falciparum subtilisin-like protease SUB1, and also inhibit parasite egress from erythrocytes. Our results indicate that the anti-malarial activity of the compounds is linked to inhibition of the SUB1 maturase plasmepsin subtype Plm X.
